KT-413: A trial testing KT-413 in people with relapsed or refractory B-cell Non-Hodgkin lymphoma
A phase 1 trial evaluating the medication KT-413 in adults with relapsed or refractory non-Hodgkin lymphoma (NHL).
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05233033
Trial aim and background
The aim of this trial is to look at how safe and well tolerated the medication KT-413 is in relapsed or refractory NHL, as well as the pharmacokinetics and pharmacodynamics.
The first stage of the trial will determine an appropriate dose of KT-413 in patients with NHL. The next stage will explore it further in patients with diffuse large B-cell lymphoma (DLBCL).
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with confirmed B-cell NHL for stage 1 of the trial, and DLBCL for stage 2 which has failed to respond to, or relapsed after two systemic treatments may be eligible for the trial.
Locations
Recruitment is taking place in the following UK locations:
- University College London Hospitals, London
- University Hospital Southampton NHS Foundation Trust, Southampton
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05233033
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.